AusBiotech 2024 is Australia's premier life science conference and the flagship event of Australia's biggest week in biotech. This year will be the biggest programme to date, featuring over 60 engaging sessions and more than 200 speakers in Melbourne from 30 October-1 November.
With the main conference opening to be delivered by The Hon. Natalie Hutchins MP, Minister for Jobs and Industry, Minister for Treaty and First Peoples, Minister for Women at Victorian Government, other programme highlights so far include:
- Philipp Ernst, Vice President of Quantum Solutions & Business Development, PsiQuantum, will present Fault tolerant quantum computing: Hardware, algorithms and their applications in biotech to providing insights on PsiQuantum's roadmap to deliver the world's first utility-scale quantum computer in Australia, and how this technology unlocks the true potential of quantum algorithms applied to quantum chemistry problems and their relevance in biotech;
- AusBiotech 2023's, Millis Orator Dr Daniel Timms, founder, BiVACOR, will discuss his journey in developing the first permanent total artificial heart. The Millis Oration is named in honour of Emeritus Professor Nancy Millis's contribution to the industry, and is held annually at the AusBiotech conference together with continuous support from CSL. The Oration is a focal point of the annual industry gathering and is appropriately named in honour of this pioneer of Australia's biotechnology industry;
- Keynote Michael Hund, global Chief Executive Officer, EB Research Partnerships (EBRP), will present on Venture into cures: How patient foundations, biotech, and academia can unite via innovative business models to accelerate treatments and cures, which will discuss how EBRP, as the largest global nonprofit dedicated to curing Epidermolysis Bullosa (EB), has raised over $60 million to fund more than 140 global scientific projects and companies through its award winning venture philanthropy and business model, growing the clinical trial landscape from two to more than 40 clinical trials, and achieving the first two FDA approved treatments in 2023, and
- Plenary and panel sessions exploring the trends, issues and opportunities for industry in radiopharmaceuticals, quantum computing, mRNA, ADCs, antimicrobial resistance, investment, clinical trials, manufacturing, commercialisation, intellectual property, artificial intelligence, and much more.
AusBiotech 2023 is created by industry, for industry; and for more than three decades it has created a forum to reflect on the sector's achievements and exchange ideas to further advance the industry. The AusBiotech team is committed to delivering a diversity across the expert speaker, chair and panellist programme. Measuring gender diversity at our conferences is part of this commitment. In 2022 AusBiotech delivered a 45% female and 55% male split and in 2023 a 48% female and 52% male split. This year, we anticipate 250 speakers will join the final programme and we are striving for a 50/50 balance.
This year's programme features a one-day AgriBiotech & BioSecurity Summit, hosted in partnership with CSIRO, the Cell & Gene Summit, hosted in partnership with Australia's Cell & Gene Catalyst a joint venture between AusBiotech and Medicines Australia, the Early-Stage Innovation Forum, the Merck-sponsored Conference Gala dinner, the Clinical Trials Dinner, and plenty of formal and informal networking opportunities.
Biotech's biggest week also includes AusBioInvest 2024, Australia's premier life science investment event, on 29 October in Melbourne, pre-conference workshops (more information to come), and site tours around Monash, Parkville, La Trobe health and innovation precincts on 29 October.
Join AusBiotech 2024 in-person to celebrate and connect with our thriving Australian and global biotechnology network. AusBiotech encourages delegates to take advantage of early-bird registrations before 27 September; register now.
AusBiotech's premier biotech conferences are proudly sponsored by the Victorian Government. Download the full programme here.
